Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sentien Biotechnologies

Request full access

A Cambridge, MA and Lexington, MA based regenerative medicine company developing cell based therapies for critical care diseases

Lexington, United StatesFounded 2008Biotech & Life Sciences

About Sentien Biotechnologies

Sentien Biotechnologies, Inc. is a clinical-stage regenerative medicine company founded in 2008 by Biju Parekkadan and Brian Miller. The company is focused on developing cell-based therapies for conditions caused by systemic, immune-mediated inflammation. Miller, the current CEO, has over 20 years of experience in the life sciences, including roles at FORMA Therapeutics and Eli Lilly and Company. Parekkadan, the scientific co-founder, is a researcher whose work on a novel method to deliver cell therapy led to the company's core technology.

The company's business is centered on its proprietary ex-vivo cell therapy platform. The lead product, SBI-101, is an extracorporeal device that combines allogeneic mesenchymal stromal cells (MSCs) with a blood filtration device. This approach avoids the direct injection of cells into the patient. Instead, the patient's blood is circulated through the device, where it is "conditioned" by anti-inflammatory and regenerative factors secreted by the MSCs. This method allows for a controlled, sustained, and dynamic delivery of the therapeutic factors, a significant advantage over traditional cell infusion methods where cells are often lost quickly. The technology is designed to integrate with existing blood-circuit equipment like dialysis or ECMO machines.

Sentien's primary market is critical care, targeting complex systemic inflammatory diseases where single-factor agents have been ineffective. The company's initial focus is on treating patients with acute kidney injury (AKI) who require dialysis. Following promising initial data, the application of SBI-101 was expanded to clinical trials for treating severe COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and AKI. The company's revenue model will likely be based on the sale of the SBI-101 device for use in hospital and critical care settings. Sentien has secured a total of $13 million in funding over two rounds, with a notable $12 million Series A round in 2017 led by Boehringer Ingelheim Venture Fund and Mission BioCapital.

Source: Dealroom company data

At a glance

Status
Operational
Employees
6
Open positions
None listed
Dealroom signal
53.8/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Surgery, Cardiology and cardiovascular, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

9 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Apr 2017 $12M $48M BioInnovation · Chiesi Ventures · MBL Venture Capital · Boehringer Ingelheim Venture Fund —
GRANTOther financing Jan 2016 $2.8M — US Department of Health and Human Services —
Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

Sentien Biotechnologies website traffic

Latest recorded traffic for Sentien Biotechnologies is 540 monthly website visits, up 20% over the last three months. Sentien Biotechnologies's team grew 0% over the past year.

Latest monthly visits540 3-month web change+20% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Sentien Biotechnologies in the Lexington ecosystem

Live from Dealroom

The Sentien Biotechnologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • US National Science Foundation
  • US Department of Health and Human Services

Series A5 investors entered at this stage

  • BioInnovation
  • Boehringer Ingelheim Venture Fund
  • Chiesi Ventures
  • MBL Venture Capital
  • Mass Medical Angels

Other known investors4 additional known investors

  • Massachusetts Institute of Technology
  • Rutgers university
  • DRIVe - Division of Research, Innovation, and Ventures
  • Mission BioCapital
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Lexington HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sentien Biotechnologies on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sentien Biotechnologies’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.